CS-801 phase 3 comparative study
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 16 Jun 2016 New trial record